Table 1.
Patient characteristics of 124 patients of whom 70 were diagnosed with PCa
| Variable | Total (n = 124) | PCa (n = 70) | No PCa (n = 54) | p-value* | |
|---|---|---|---|---|---|
| PSA | Mean (Median; 95 %CI) | 9.1 (7.2; 8.3-9.9) | 9.7 (7.7; 8.5-11.0) | 8.3 (6.7; 7.2-9.4) | 0.090* |
| PCA3-score | Mean (Median; 95 %CI) | 53.1 (33.5; 42.9-63.4) | 73.6 (53.5; 57.7-89.6) | 26.6 (19.0; 19.9-33-2) | <0.001* |
| Prostate volume | Mean (Median; 95 %CI) | 60.0 (53.0; 54.7-65.4) | 49.9 (43.5; 44.7-55.1) | 73.2 (66.5; 63.8-82.5) | <0.001* |
| Age | Mean (Median; 95 %CI) | 64.0 (65.1; 62.9-65.2) | 64.9 (65.7; 63.5-66.2) | 62.9 (63.0; 61.0-64.9) | 0.094* |
| Positive DRE | Number (%) | 31 (25 %) | 22 (31 %) | 9 (17 %) | 0,060** |
| Clinical stage | Number (%) | ||||
| T1c | 35 (50 %) | ||||
| T2a | 12 (17 %) | ||||
| T2b | 6 (9 %) | ||||
| T2c | 11 (16 %) | ||||
| T3a | 6 (9 %) | ||||
| Gleason score | Number (%) | ||||
| 3 + 2 = 5 | 1 (1 %) | ||||
| 3 + 3 = 6 | 21 (26 %) | ||||
| 3 + 4 = 7a | 15 (19 %) | ||||
| 4 + 3 = 7b | 9 (11 %) | ||||
| 4 + 4 = 8 | 5 (6 %) | ||||
| 4 + 5 = 9 | 4 (5 %) | ||||
| 5 + 4 = 9 | 2 (2 %) | ||||
| EAU-risk | Number (%) | ||||
| Low-risk | 21 (30 %) | ||||
| Intermediate-risk | 32 (46 %) | ||||
| High-risk | 17 (24 %) |
PCa prostate cancer, PSA prostate specific antigen, PCA3 prostate cancer gene 3, DRE digital rectal examination is considered positive if there was suspicion of PCa
*p-value is estimated for the difference of means between the group with PCa and the group without PCa using the t-test
**p-value is estimated for the difference of proportions between the group with PCa and the group without PCa using Chi-square test